Replies to post #201 on Vanda Pharmaceuticals, Inc. (VNDA)

[surf1944]

4:01PM Vanda Pharma Initiates Phase III clinical study aimed at resetting the body clock (VNDA) 6.36 +0.01 : Co announced it has initiated a Phase III clinical trial to evaluate tasimelteon in patients with non-24-hour sleep wake disorder, a condition experienced primarily by totally blind individuals that results in abnormal night sleep patterns and chronic daytime sleepiness.